14
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The British Society for Sexual Medicine Guidelines on Male Adult Testosterone Deficiency, with Statements for Practice

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Testosterone deficiency (TD) is an increasingly common problem with significant health implications, but its diagnosis and management can be challenging. A multi-disciplinary panel from BSSM reviewed the available literature on TD and provide evidence-based statements for clinical practice. Evidence was derived from Medline, EMBASE and Cochrane searches on hypogonadism, testosterone therapy (T Therapy) and cardiovascular safety from May 2017 to September 2022. This revealed 1,714 articles, including 52 clinical trials and 32 placebo-controlled randomised controlled trials. A total of twenty-five statements are provided, relating to five key areas: screening, diagnosis, initiating T Therapy, benefits and risks of T Therapy, and follow-up. Seven statements are supported by level 1 evidence, eight by level 2, five by level 3, and five by level 4. Recent studies have demonstrated that low levels of testosterone in men are associated with increased risk of incident type 2 diabetes mellitus, worse outcomes in chronic kidney disease and COVID 19 infection with increased all-cause mortality, along with significant quality of life implications. These guidelines should help practitioners to effectively diagnose and manage primary and age-related TD.

          Related collections

          Most cited references156

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission

          Anecdotal evidence suggests that Coronavirus disease 2019 (COVID-19), caused by the coronavirus SARS-CoV-2, exhibits differences in morbidity and mortality between sexes. Here, we present a meta-analysis of 3,111,714 reported global cases to demonstrate that, whilst there is no difference in the proportion of males and females with confirmed COVID-19, male patients have almost three times the odds of requiring intensive treatment unit (ITU) admission (OR = 2.84; 95% CI = 2.06, 3.92) and higher odds of death (OR = 1.39; 95% CI = 1.31, 1.47) compared to females. With few exceptions, the sex bias observed in COVID-19 is a worldwide phenomenon. An appreciation of how sex is influencing COVID-19 outcomes will have important implications for clinical management and mitigation strategies for this disease.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.

            Development of these guidelines is mandated by the American Association of Clinical Endocrinologists (AACE) Board of Directors and the American College of Endocrinology (ACE) Board of Trustees and adheres to published AACE protocols for the standardized production of clinical practice guidelines (CPGs).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Adverse events associated with testosterone administration.

              Testosterone supplementation has been shown to increase muscle mass and strength in healthy older men. The safety and efficacy of testosterone treatment in older men who have limitations in mobility have not been studied. Community-dwelling men, 65 years of age or older, with limitations in mobility and a total serum testosterone level of 100 to 350 ng per deciliter (3.5 to 12.1 nmol per liter) or a free serum testosterone level of less than 50 pg per milliliter (173 pmol per liter) were randomly assigned to receive placebo gel or testosterone gel, to be applied daily for 6 months. Adverse events were categorized with the use of the Medical Dictionary for Regulatory Activities classification. The data and safety monitoring board recommended that the trial be discontinued early because there was a significantly higher rate of adverse cardiovascular events in the testosterone group than in the placebo group. A total of 209 men (mean age, 74 years) were enrolled at the time the trial was terminated. At baseline, there was a high prevalence of hypertension, diabetes, hyperlipidemia, and obesity among the participants. During the course of the study, the testosterone group had higher rates of cardiac, respiratory, and dermatologic events than did the placebo group. A total of 23 subjects in the testosterone group, as compared with 5 in the placebo group, had cardiovascular-related adverse events. The relative risk of a cardiovascular-related adverse event remained constant throughout the 6-month treatment period. As compared with the placebo group, the testosterone group had significantly greater improvements in leg-press and chest-press strength and in stair climbing while carrying a load. In this population of older men with limitations in mobility and a high prevalence of chronic disease, the application of a testosterone gel was associated with an increased risk of cardiovascular adverse events. The small size of the trial and the unique population prevent broader inferences from being made about the safety of testosterone therapy. (ClinicalTrials.gov number, NCT00240981.) 2010 Massachusetts Medical Society
                Bookmark

                Author and article information

                Journal
                World J Mens Health
                World J Mens Health
                WJMH
                The World Journal of Men's Health
                Korean Society for Sexual Medicine and Andrology
                2287-4208
                2287-4690
                July 2023
                22 February 2023
                : 41
                : 3
                : 508-537
                Affiliations
                [1 ]Department of Urology, Spire Hospital, Little Aston, Birmingham, UK.
                [2 ]Department of Urology, Aston University, Birmingham, UK.
                [3 ]Trends in Urology and Men’s Health, Letchworth, UK.
                [4 ]Faculty of Health & Human Sciences, University of Hertfordshire & The Prostate Centre, London, UK.
                [5 ]Department of Urology, University Hospital Southampton and UCLH, London, UK.
                [6 ]Department of Endocrinology, Barnsley Hospital, Barnsley, UK.
                [7 ]Department of Biochemistry, Royal Hallamshire Hospital, University of Sheffield Medical School, Sheffield, UK.
                [8 ]Division of Surgery and Interventional Science, NIHR Biomedical Research Centre UCLH, London, UK.
                [9 ]Department of Biochemistry, Black Country Pathology Services, Walsall Manor Hospital, Walsall, UK.
                [10 ]Cardiff and Vale NHS Trust, Cardiff, UK.
                [11 ]University of South Wales TDS, Bridgend, UK.
                [12 ]Department of Cardiology, University of Cape Coast, Cape Coast, Ghana.
                [13 ]Portway Surgery, Porthcawl, UK.
                [14 ]Leamington Spa, UK.
                [15 ]Department of Nephrology, NCA, Salford Royal Hospital, Salford, UK.
                [16 ]Department of Clinical Biochemistry, University Hospitals Birmingham NHS Foundation Trust, Sutton Coldfield, West Midlands, UK.
                Author notes
                Correspondence to: Geoffrey Hackett. Holly Cottage Clinic, Fisherwick Rd, Lichfield, Staffordshire, WS14 9JL, UK. Tel: +44-1543432757, hackettgeoff@ 123456gmail.com
                Author information
                https://orcid.org/0000-0003-2274-111X
                https://orcid.org/0000-0003-3182-0151
                https://orcid.org/0000-0002-9158-8393
                https://orcid.org/0000-0003-2958-1614
                https://orcid.org/0000-0001-6878-0769
                https://orcid.org/0000-0003-2783-6783
                https://orcid.org/0000-0002-2099-9857
                https://orcid.org/0000-0002-1845-4954
                https://orcid.org/0000-0001-7652-1572
                https://orcid.org/0000-0003-2299-4133
                Article
                10.5534/wjmh.221027
                10307648
                36876744
                bc41da96-f7cf-416d-ba3c-76be781b2398
                Copyright © 2023 Korean Society for Sexual Medicine and Andrology

                This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 23 October 2022
                : 07 November 2022
                : 23 November 2022
                Funding
                Funded by: British Society for Sexual Medicine;
                Categories
                Review Article
                Hormonal Regulation of Male Reproduction and Hypogonadism

                erectile dysfunction,hypogonadism,testosterone deficiency,testosterone therapy

                Comments

                Comment on this article